BS_7B89YR6K
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- overall_survival_months
- 123.24
- os_event
- true
- age_years
- 0.529
- sex
- M
- race
- White
- e1_e2
- E1
- umap1_2d
- -2.295104152
- umap2_2d
- 3.679953571
- umap1_3d
- 1.472684504
- umap2_3d
- 0.786756548
- umap3_3d
- -0.762487403
- dataset
- EPN-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.450
- HEDGEHOG_SIGNALING+0.350
- APICAL_SURFACE+0.340
- PANCREAS_BETA_CELLS+0.320
- MYOGENESIS+0.290
- SPERMATOGENESIS+0.190
- ESTROGEN_RESPONSE_EARLY+0.130
- KRAS_SIGNALING_UP+0.110
- INFLAMMATORY_RESPONSE+0.100
- ESTROGEN_RESPONSE_LATE+0.050
Top 10 suppressed
- MYC_TARGETS_V1-0.670
- DNA_REPAIR-0.590
- E2F_TARGETS-0.570
- G2M_CHECKPOINT-0.530
- MYC_TARGETS_V2-0.520
- OXIDATIVE_PHOSPHORYLATION-0.510
- PROTEIN_SECRETION-0.490
- INTERFERON_ALPHA_RESPONSE-0.420
- NOTCH_SIGNALING-0.420
- UNFOLDED_PROTEIN_RESPONSE-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_QV51J756 | Ganglioglioma | — | 0.963 |
| 2 | BS_ZR96A4FH | DNET | — | 0.961 |
| 3 | MNG906 | — | — | 0.952 |
| 4 | BS_C7N3J4NW | high-grade glioma | — | 0.951 |
| 5 | BS_6MY8W3H0 | DNET | — | 0.951 |
| 6 | BS_TCGEZJ5F | EPN | Supratentorial EPN | 0.947 |
| 7 | BS_TCGEZJ5F | Supratentorial Ependymoma | — | 0.943 |
| 8 | BS_K5802F84 | pilocytic astrocytoma | — | 0.943 |
| 9 | BS_7B89YR6K | Posterior Fossa Ependymoma | — | 0.941 |
| 10 | BS_KPT2WPHW | Ganglioglioma | — | 0.941 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.450 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.350 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.340 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.290 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.110 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |